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Numerous casein and whey protein-derived angiotensin-I-converting enzyme (ACE) inhibitory
peptides/hydrolysates have been identified. Clinical trials in hypertensive animals and humans
show that these peptides/hydrolysates can bring about a significant reduction in hypertension.
These peptides/hydrolysates may be classified as functional food ingredients and nutraceuticals
due to their ability to provide health benefits i.e. as functional food ingredients in reducing the
risk of developing a disease and as nutraceuticals in the prevention/treatment of disease.
Peptides/hydrolysates: Hypertension: Functional foods/nutraceuticals
Introduction
Angiotensin-I-converting enzyme (ACE) is a key enzyme
in the regulation of peripheral blood pressure. ACE, a
dipeptide-liberating carboxypeptidase (peptidyldipeptide
hydrolase, EC 3.4.15.1), classically associated with the
renin±angiotensin system, converts angiotensin I into
angiotensin II, a highly potent vasoconstrictor molecule
(Skeegs et al. 1956). Several endogenous peptides such as
enkephalins, bradykinin and substance P are inhibitors and
competitive substrates for ACE (Maruyama et al. 1987a;
Steve et al. 1988). In the kinin kallikrein system, for
example, ACE activates bradykinin, a vasodilatory mole-
cule (Erdos, 1975). This enzyme, therefore, plays a key
physiological role in the regulation of local levels of
several endogenous bioactive peptides. Exogenous ACE
inhibitors having an antihypertensive effect in vivo were
first discovered in snake venom (Ondetti et al. 1977).
Several food protein sources including fish, gelatin and
maize protein contain ACE-inhibitory peptides (for reviews
see Ariyoshi, 1993; Meisel, 1993). Milk proteins are also
precursors for a range of peptides which inhibit ACE
(Meisel, 1993; Takano, 1998; FitzGerald & Meisel, 1999).
Casein-derived inhibitors of ACE are known as casokinins
(Meisel, 1993), whereas whey-derived inhibitors are known
as lactokinins (FitzGerald & Meisel, 1999).
General structural features of milk protein-derived
ACE inhibitory peptides
Casokinin sequences have been found in as1-, b-, and k-
casein, and lactokinins in a-lactalbumin, b-lactoglobulin
and bovine serum albumin (Tables 1 and 2). Two strategies
have generally been used in the identification and
characterisation of such peptides, i.e. isolation of inhibitory
peptides from in vitro enzymatic digests of milk proteins
and chemical synthesis of peptides or peptide analogues
having similar structures to those known to inhibit ACE.
Structure±activity correlations between different peptide
inhibitors of ACE indicate that binding to ACE is strongly
influenced by the C-terminal tripeptide sequence of the
substrate. Although the precise substrate specificity is not
fully understood, ACE appears to prefer substrates or
competitive inhibitors containing hydrophobic (aromatic or
branched side-chains) amino acid residues at each of the
three C-terminal positions. ACE inhibition studies with
dipeptides of varying structure, show that C-terminal
tryptophan, tyrosine, phenylalanine or proline residues
were most effective in enhancing substrate binding
(Cheung et al. 1980). All casokinins, i.e. casein-derived
ACE inhibitory peptides have proline, lysine or arginine as
the C-terminal residue (Table 1). However, the presence of
positively charged C-terminal lysine or arginine residues in
casokinins, bradykinin and some synthetic inhibitors
(Cheung et al. 1980) does not fit with the ACE active
site model proposed by Ondetti & Cushman (1982).
Nevertheless, structure±activity data suggest that the
positive charge on the guanidino or 1-amino group of C-
terminal arginine and lysine side-chains, respectively,
contribute substantially to inhibitory potency. For example,
replacement of arginine at the C-terminus of bradykinin
results in an essentially inactive analogue (Meisel, 1993). It
is postulated that the mechanism of ACE inhibition
involves inhibitor interaction with an anionic binding site
which is distinct from the catalytic site. Given the above, it
is expected that peptide conformation, i.e. the structure
adopted in a specific environment, should contribute to
ACE inhibitor potency. A detailed knowledge of the
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mechanism of action of ACE and the conformational
behaviour of ACE inhibitory peptides should lead to a
better understanding of the antihypertensive potential of
milk protein-derived peptides.
Physiological effects
ACE is widely distributed in mammalian tissues. It is
present in plasma, lung, kidney, heart, skeletal muscle,
Table 1. Bovine casein-derived angiotensin-I-converting enzyme (ACE) inhibitory peptides*
Peptide fragment/analogue
Primary structure
(one letter code)
IC50
²
(m mol/l)
Enzymatic
hydrolysis
Peptide
synthesis Reference
aS1-casein f (23±34) FFVAPFPEVFGK 77 + 2 Maruyama & Suzuki, 1982; Maruyama et al. 1985
f (23±37) FFVAP 6 + 2 Maruyama et al. 1985
f (24±27) FVAP 10 2 + Maruyama et al. 1987a
f (25±27) VAP 2 2 + Maruyama et al. 1987a
f (27±30) PFPE > 1000 2 + Maruyama et al. 1987a
f (28±34) FPEVFGK 140 + 2 Maruyama et al. 1987a
f (32±34) FGK 160 2 + Maruyama et al. 1987a
f (104±109) YKVPQL 22 + 2 Maeno et al. 1996
f (142±147) LAYFYP 65 + 2 Pihlanto-LeppaÈ laÈ et al. 1998
f (143±148) AYFYPE 106³ + 2 Yamamoto et al. 1994
f (157±164) DAYPSGAW 98 + 2 Pihlanto-LeppaÈ laÈ et al. 1998
f (194±199) TTMPLW 16 + 2 Maruyama et al. 1987b
f (197±199) PLW 36 2 + Maruyama et al. 1987b
f (198±199) LW 50 2 + Maruyama et al. 1987b
b-casein f (57±64) SLVLPVPE 39 + 2 Yamamoto et al. 1994
f (60±66) YPFPGPIP 500 2 1 Meisel & Schlimme, 1994
f (74±76) IPP 5 + 2 Nakamura et al. 1995
f (84±86) VPP 9 + 2 Nakamura et al. 1995
f (108±113) EMPFPK 423³ + 2 Pihlanto-LeppaÈ laÈ et al. 1998
f (169±174) KVLPVP 5 2 + Maeno et al. 1996
f (169±175) KVLPVPQ 1000 + 2 Maeno et al. 1996
f (177±179) AVP 340 2 + Maruyama et al. 1987a
f (177±181) AVPYP 80 2 + Maruyama et al. 1987a
f (177±183) AVPYPQR 15 + 2 Maruyama et al. 1987a
f (179±181) PYP 220 2 + Maruyama et al. 1987a
f (181±183) PQR .400 + 2 Maruyama et al. 1987a
f (193±198) YQQPVL 280 + 2 Pihlanto-LeppaÈ laÈ et al. 1998
f (193±202) YQQPVLGPVR 300 2 + Meisel & Schlimme, 1994
k-casein f (25±34) YIPIQYVLSR nd 2 + Chiba & Yoshikawa, 1991
f (35±41) YPSYGLNY nd 2 + Chiba & Yoshikawa, 1991
f (58±59)§ YP 720 + + Yamamoto et al. 1999
f (108±110) IPP 5 + 2 Nakamura et al. 1995
nd, not determined.
* Details of other casein-derived peptides/or related peptides which inhibit ACE are available within the references used to generate this Table.
² Peptide concentration required to inhibit ACE by 50 %.
³ IC50 value given in mg/ml.
§ This sequence also occurs in aS1-casein f(146±147) and f(159±160) and in b-casein f(114±115).
Table 2. Whey protein-derived angiotensin-I-converting enzyme (ACE) inhibitory peptides
Peptide fragment/analogue
Primary structure
(one letter code)
IC50*
(mmol/l)
Enzymatic
hydrolysis
Peptide
synthesis Reference
a-lactalbumin f (50±51) YG 1523 2 + Mullally et al. 1996
f (50±53) YGLF 733 + + Mullally et al. 1996
f (52±53) LF 349 2 + Mullally et al. 1996
f (105±110) LAHKAL 621 + 2 Pihlanto-LeppaÈ laÈ et al. 1998
b-lactoglobulin f (9±14) GLDIQK 580 + 2 Pihlanto-LeppaÈ laÈ et al. 1998
f (15±20) VAGTWY 1682 + 2 Pihlanto-LeppaÈ laÈ et al. 1998
f (102±103) YL 122 2 + Mullally et al. 1996
f (102±105) YLLF 172 + + Mullally et al. 1996
f (104±105) LF 349 2 + Mullally et al. 1996
f (142±148) ALPMHIR 43 + + Mullally et al. 1997b
f (146±148) HIR 953 2 + Mullally et al. 1997b
f (146±149) HIRL 1153 2 + Mullally et al. 1996
f (147±148) IR 695 2 + Mullally et al. 1996
f (148±149) RL 2439 2 + Mullally et al. 1996
Bovine serum albumin f (208±216) ALKAWSVAR 3 2 + Chiba & Yoshikawa, 1991
* Peptide concentration required to inhibit ACE by 50 %.
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pancreas, spleen, placenta, arteries, testes, uterus and brain.
It is also present as a brush border membrane-bound
enzyme on epithelial cells of human jejunum (Ondetti &
Cushman, 1982; Steve et al. 1988).
A number of studies in spontaneously hypertensive rats
(SHR) have demonstrated an antihypertensive effect
following intraveneous and oral ingestion of casein-derived
ACE inhibitory peptides. These peptides correspond to
tryptic (Maruyama et al. 1987b) and Lactobacillus
helveticus protease (Yamamoto et al. 1994, 1999) digests
of as1-, b- and k-casein. Oral ingestion of a tryptic digest of
whole casein gave an antihypertensive effect in SHR
(Karaki et al. 1990). A study in normotensive and mildly
hypertensive human volunteers reported that twice daily
ingestion of 10 g of a tryptic digest of casein for 4 weeks
had an antihypertensive effect (Sekiya et al. 1992). A
placebo-controlled study in hypertensive humans defini-
tively demonstrated a significant reduction in blood
pressure following daily ingestion of 95 ml of Calpis sour
milk (Hata et al. 1996). Milk fermented with Calpis sour
milk starter (L. helveticus and Saccharomyces cerevisiae)
contains highly potent tripeptide inhibitors of ACE, i.e.
Val-Pro-Pro (b-casein f(84±86)) and Ile-Pro-Pro (b-casein
f(74±76)) and k-casein f(108±110)), (Nakamura et al.
1995). It is worth noting that the ingested dose of these
ACE inhibitory peptides was in the range of only 1´2±
1´6 mg.
ACE inhibitory peptides can be produced during the
manufacture of a range of dairy products. Meisel et al.
(1997) demonstrated that secondary proteolysis during
cheese ripening leads to the production of ACE inhibitory
peptides. The ACE inhibitory activity in cheese was mainly
associated with the low-molecular-weight peptide fraction.
It was also demonstrated that low levels of proteolysis, in
for example, fresh cheese, quarg, yoghurt and protein
hydrolysate supplemented sports nutrition products, were
associated with low ACE inhibitory index values (Meisel
et al. 1997). Rokka et al. (1997) demonstrated the presence
of ACE inhibitory peptides (i.e. b-casein f(177±183) and
f(193±202)) in UHT milk prefermented with Lactobacillus
casei ssp. rhamnosus and subsequently digested with
pepsin and trypsin. Recently, Mullally et al. (1997a)
showed that endoproteinase (trypsin, chymotrypsin, elas-
tase and pepsin) digests of whey protein concentrate and
fractions enriched in a-lactalbumin and b-lactoglobulin
could inhibit ACE in vitro. Furthermore, a tryptic fragment
of b-lactoglobulin (Ala-Leu-Pro-Met-His-Ile-Arg, f(142±
148)) was identified having an ACE IC50  42´6mmol=l
(Mullally et al. 1997b). Pihlanto-LeppaÈlaÈ et al. (1998)
identified several casein (as1- and b-casein) and whey (a-
lactalbumin and b-lactoglobulin) derived ACE inhibitory
peptides following digestion of cheese whey and isoelectric
casein with pepsin and trypsin. No animal or human studies
are as yet available on the antihypertensive potential of
whey protein-derived hydrolysates/peptides. However, it
has been reported that food-derived ACE inhibitory
peptides with IC50 values in the range 100±500 mmol/l
can be of nutritive/physiological importance in that they
could be active following oral administration (Sekiya et al.
1992). The majority of the peptides listed in Tables 1 and 2
have ACE inhibitory potencies within this range. It is
noteworthy that Yamamoto et al. (1999) demonstrated that
Tyr-Pro, having an ACE IC50 value of 720 mmol/l, could
mediate a significant hypotensive effect in SHR. Tyr-Pro,
which can arise from as1-casein f(146±147) and f(159±
160), b-casein f(114±115) and k-casein f(58±59), was
found in skim milk fermented with Lactobacillus helveticus
CPN4. The Tyr-Pro dipeptide may result from the
hydrolytic action of starter derived post-proline dipeptidyl
aminopeptidase (PPDA) activity on casein peptides. PPDA
releases amino acyl proline moieties from the N-terminus
of peptides (Bouchier et al. 1999).
The antihypertensive potential of milk protein-derived
peptides is dependent on the ability of these peptides to
reach their target site without being degraded and as a
consequence inactivated by the action of intestinal or
plasma peptidases. Inhibition of ACE in lung, vascular,
kidney and brain tissue by captopril, a drug commonly used
in the control of blood pressure, is thought to be central to
the antihypertensive effect (Velletri & Bean, 1982; Unger
et al. 1985). Resistance to peptidase degradation may be a
prerequisite for an antihypertensive effect during the oral
ingestion and the intravenous infusion of ACE inhibitory
hydrolysates/peptides. For example, as1-casein f(23±27), a
potent ACE inhibitor in vitro, was shown to have no
hypotensive effect in vivo (Maruyama et al. 1987b). A
similar situation has been shown by Maeno et al. (1996) in
the case of as1-casein f(104±109). The presence of Val-
Pro-Pro and Ile-Pro-Pro in heat-treated solubilised aortal
fractions of SHR fed on Calpis sour milk demonstrates the
resistance of these peptides to intestinal and circulatory
peptidases in addition to the absorption of these peptides
from the intestine (Masuda et al. 1996). Proline-containing
peptides are generally resistant to degradation by digestive
enzymes (Kim et al. 1972; Adibi & Kim, 1981).
Furthermore, tripeptides containing C-terminal Pro-Pro
are reported to be resistant to proline specific peptidases
(Yoshimoto et al. 1978; Mock et al. 1990). It is interesting
that the tryptic peptide, b-lactoglobulin f(142±148), was
resistant to further degradation by pepsin and chymotrypsin
(Mullally et al. 1997b). On the other hand, peptide
degradation or fragmentation may result in more potent
ACE inhibitory activities. For example, removal of C-
terminal glutamine from b-casein f(169±175) increased the
in vitro ACE inhibitory potency from 1000 to 5 mmol/l,
however, both b-casein f(169±174) and f(169±175) had
strong antihypertensive activities in SHRs (Maeno et al.
1996). These results emphasise the necessity of performing
in vivo studies in all cases.
Several casein and whey protein-derived ACE inhibitory
peptides having other biological activities have been
reported. Albutensin A, bovine serum albumin f(208±
216), displays ileum contracting and relaxing activities in
addition to ACE inhibitory activity (Chiba & Yoshikawa,
1991). The casein-derived opioid peptide, b-casomorphin 7
also inhibits ACE (Meisel & Schlimme, 1994). Recently, it
was demonstrated that b-lactorphin, the whey protein-
derived opioid peptide could inhibit ACE (Mullally et al.
1996). This multifunctional bioactivity nature of milk
protein peptides merits further research in terms of the
general nutritive/physiological consequences of milk pro-
tein ingestion.
S35ACE inhibitory peptides
The majority of milk protein-derived peptides reported to
date do not have ACE inhibitory potencies (Tables 1 and 2)
approaching that of captopril IC50  0´006mmol=l:
However, being naturally derived these peptides would be
expected not to have the side-effects associated with
synthetically produced drugs used in the control of
hypertension, i.e. cough and alterations in serum lipid
metabolism (Ames, 1983; Seseko & Kaneko, 1985;
Nakamura, 1987).
Conclusion
Casokinins and lactokinins represent a group of bioactive
peptides that have significant potential as naturally-derived
agents for the prevention/control of blood pressure and
related diseases. The widespread use of these peptides in
functional foods/nutraceuticals requires ongoing studies,
including extended clinical trials, to demonstrate their long-
term efficacy and safety.
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